A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease, Huntington's Disease

In brief

To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation.

Key facts

Study ID

NCT00990613

Run by

Pfizer

People needed

19

Starts

2009-10-01

Expected to finish

2010-01-01

Last updated by the study team

2010-02-03

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Caucasian, male or females, 50 to 85 years inclusive.
• Subjects must have adequate space available on each side of the upper or middle back that is free from excessive hair, broken or irritated skin, tattoos, scars, moles, acne, and sunburn.

You may not qualify if…

• Evidence or history of any major medical or psychiatric illness or unstable medical condition within six months of Screening that may increase the risk associated with study participation.
• Subjects with any central nervous system disease including Alzheimer's disease, Parkinson's disease, Huntington disease, or any form of dementia.
• Subjects with any history of stroke, known cerebrovascular disease or subjects with any history of structural brain disease.
• Any history of epilepsy, seizure disorder (i.e., including febrile seizures) or convulsion.
• Subjects with any skin disorders that might prevent application of the dimebon solution including, but not limited to, any known sensitivity to adhesives.

Where it is running

• Pfizer Investigational Site — Kalamazoo, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.